These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 16549970

  • 21. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J, Bani-Sadr F, Gassin M, Raffi F.
    Clin Infect Dis; 2001 Mar 15; 32(6):963-9. PubMed ID: 11247719
    [Abstract] [Full Text] [Related]

  • 22. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.
    J Med Virol; 2007 Nov 15; 79(11):1664-70. PubMed ID: 17854034
    [Abstract] [Full Text] [Related]

  • 23. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
    Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngolé E, Ducos J, Delaporte E, Laurent C.
    Antivir Ther; 2012 Nov 15; 17(2):321-6. PubMed ID: 22290198
    [Abstract] [Full Text] [Related]

  • 24. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct 15; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 25. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA, Sucupira MV, Arabe J, Gomes SA.
    BMC Infect Dis; 2004 Aug 31; 4():29. PubMed ID: 15339340
    [Abstract] [Full Text] [Related]

  • 26. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C, Liotta G, Andreotti M, Luhanga R, Jere H, Mancinelli S, Maulidi M, Sagno JB, Pirillo M, Erba F, Amici R, Ceffa S, Marazzi MC, Vella S, Palombi L, Giuliano M.
    J Med Virol; 2012 Oct 31; 84(10):1553-7. PubMed ID: 22930502
    [Abstract] [Full Text] [Related]

  • 27. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.
    J Hum Virol; 1999 Oct 31; 2(6):344-9. PubMed ID: 10774551
    [Abstract] [Full Text] [Related]

  • 28. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.
    Roque-Afonso AM, Férey MP, Mackiewicz V, Fki L, Dussaix E.
    Antivir Ther; 2003 Dec 31; 8(6):627-34. PubMed ID: 14760897
    [Abstract] [Full Text] [Related]

  • 29. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 31; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 30. [Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients].
    Rey D, Fritsch S, Schmitt C, Partisani M, Kempf-Durepaire G, Nicolle M, Krantz V, De Mautort E, Stoll-Keller F, Lang JM.
    Gastroenterol Clin Biol; 2000 Jan 31; 24(1):125-7. PubMed ID: 10679599
    [Abstract] [Full Text] [Related]

  • 31. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 32. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM.
    J Med Virol; 2007 Oct 15; 79(10):1464-71. PubMed ID: 17705185
    [Abstract] [Full Text] [Related]

  • 33. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG, Song E, Burnett RJ, Mphahlele MJ.
    J Med Virol; 2009 Jun 15; 81(6):996-1001. PubMed ID: 19382250
    [Abstract] [Full Text] [Related]

  • 34. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
    Treviño A, Soriano V, Madejon A, Rodriguez C, Barros C, Botecchia M, Tuma P, Del Romero J, de Mendoza C.
    AIDS Res Hum Retroviruses; 2009 Dec 15; 25(12):1273-6. PubMed ID: 20001517
    [Abstract] [Full Text] [Related]

  • 35. [Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
    Wang C, Sun J, Chen JJ, Wang ZH, Hou JL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May 15; 28(5):729-30. PubMed ID: 18504191
    [Abstract] [Full Text] [Related]

  • 36. Lamivudine useful against hepatitis B-HIV co-infection.
    Prescott LM.
    J Int Assoc Physicians AIDS Care; 1995 Jun 15; 1(5):34. PubMed ID: 11362610
    [Abstract] [Full Text] [Related]

  • 37. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.
    Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J, EuroSIDA.
    J Antimicrob Chemother; 2010 Mar 15; 65(3):548-55. PubMed ID: 20051475
    [Abstract] [Full Text] [Related]

  • 38. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 39. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.
    J Viral Hepat; 2007 Mar 15; 14(3):176-82. PubMed ID: 17305883
    [Abstract] [Full Text] [Related]

  • 40. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD.
    Hepatology; 1998 Jun 15; 27(6):1670-7. PubMed ID: 9620341
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.